慢性肾脏病与肾脏或尿路上皮恶性肿瘤风险:系统评价与荟萃分析
该系统评价与荟萃分析纳入6项队列研究共8 617 563人,评估未透析或肾移植的中度及以上CKD患者发生肾脏癌症和尿路上皮癌的风险。结果显示CKD与肾脏癌症和尿路上皮癌的未调整发病率和调整后风险均升高相关,且CKD 3期和4/5期均观察到风险升高。
要点
- CKD患者肾脏癌症调整后风险升高(aHR 2.04)。
- CKD患者尿路上皮癌调整后风险升高(aHR 1.35)。
- CKD 3期及4/5期均与肾脏癌症和尿路上皮癌风险升高相关。
核心结论
- 即使是中度CKD也与肾脏癌症和尿路上皮癌风险升高相关。
- 临床医生在管理CKD患者时应考虑这些升高的风险,尤其在评估血尿的存在和病因时。
研究设计与样本
- 系统评价与荟萃分析,检索4个电子数据库至2023年5月25日。
- 纳入6项原始队列研究,共8 617 563人,对象为至少中度CKD且未透析或肾移植者。
- 使用纽卡斯尔-渥太华量表进行质量评价,采用随机效应模型进行荟萃分析。
主要发现
- 与无CKD者相比,CKD患者肾脏癌症未调整发病率比IRR 3.36(95%CI 2.32-4.88),调整后风险比aHR 2.04(95%CI 1.77-2.36)。
- 与无CKD者相比,CKD患者尿路上皮癌未调整发病率比IRR 3.96(95%CI 2.44-6.40),调整后风险比aHR 1.35(95%CI 1.22-1.50)。
- CKD 3期患者肾脏癌症aHR 1.89(95%CI 1.56-2.30),尿路上皮癌aHR 1.35(95%CI 1.20-1.52)。
- CKD 4/5期患者肾脏癌症aHR 2.30(95%CI 2.00-2.66),尿路上皮癌aHR 1.24(95%CI 1.04-1.49)。
临床怎么用
- 在管理CKD患者时,尤其评估血尿的存在和病因时,应考虑肾脏癌症和尿路上皮癌风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) is highly prevalent, affecting approximately 11% of US adults. Multiple studies have evaluated a potential association between CKD and urinary tract malignancies. Summary estimates of urinary tract malignancy risk in CKD patients with and without common co-existing conditions may guide clinical practice recommendations. METHODS: Four electronic databases were searched for original cohort studies evaluating the association between CKD and urinary tract cancers (kidney cancer and urothelial carcinoma) through 25 May 2023, in persons with at least moderate CKD and no dialysis or kidney transplantation. Quality assessment was performed for studies meeting inclusion criteria using the Newcastle-Ottawa Scale. Meta-analysis with a random-effects model was performed for unadjusted incidence rate ratios (IRR) as well as adjusted hazard ratios (aHR) for confounding conditions (diabetes, hypertension and/or tobacco use), shown to have association with kidney cancer and urothelial carcinoma. Sub-analysis was conducted for estimates associated with CKD stages separately. RESULTS: Six cohort studies with 8 617 563 persons were included. Overall, the methodological quality of the studies was good. CKD was associated with both higher unadjusted incidence and adjusted hazard of kidney cancer (IRR 3.36, 95% confidence interval (CI) 2.32-4.88; aHR 2.04, 95% CI 1.77-2.36) and urothelial cancer (IRR 3.96, 95% CI 2.44-6.40; aHR 1.35, 95% CI 1.22-1.50) compared with persons without CKD. Examining incident urinary tract cancers by CKD severity, risks were elevated in stage 3 CKD (kidney aHR 1.89, 95% CI 1.56-2.30; urothelial carcinoma aHR 1.35, 95% CI 1.20-1.52) as well as in stages 4/5 CKD (kidney cancer aHR 2.30, 95% CI 2.00-2.66; urothelial carcinoma aHR 1.24, 95% CI 1.04-1.49). CONCLUSIONS: Even moderate CKD is associated with elevated risk of kidney cancer and urothelial carcinoma. Providers should consider these elevated risks when managing individuals with CKD, particularly when considering evaluation for the presence and etiology of hematuria.
引用
- Brooks ER, Siriruchatanon M, Prabhu V, et al. Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis. Nephrol Dial Transplant. 2024. PMID: 38037426. doi:10.1093/ndt/gfad249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。